Reata Pharmaceuticals today announced the enrollment of the first patient in the pivotal Part 2 of the MOXIe trial to evaluate omaveloxolone in patients with Friedreich’s ataxia (FA).
"Friedreich’s ataxia is a severe, neurological disorder that profoundly impacts patients and their families. Based on the results from Part 1 of MOXIe, we are optimistic that Part 2 of the MOXIe trial could position omaveloxolone to become the first therapy approved for patients with Friedreich’s ataxia," said Warren Huff, Reata's Chief Executive Officer and President. "With the initiation of Part 2 of MOXIe, Reata has launched three pivotal programs in the last 12 months."
Read the entire Press Release HERE